Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

SinuShunt – New disruptive medical device for treatment of hydrocephalus

Project description

An innovative shunt for treating hydrocephalus

Hydrocephalus is a serious condition associated with the accumulation of cerebrospinal fluid (CSF) in the brain. Treatment consists of the implantation of a shunting device to drain CSF into the chest or abdomen. The scope of the EU-funded SINUSHUNT project is to develop a novel implantable medical device that drains CSF into the sinus vein, which is a natural resorption place of CSF. The use of innovative stent technology overcomes the obstruction issues associated with conventional outlets and increases the lifetime of the shunt, reducing the need for re-operation and other complications.

Objective

Hydrocephalus is a devastating neurological condition caused by accumulation of cerebrospinal fluid (CSF) on brain, and If left untreated, it can be fatal. The only treatment option is surgical, either implantation of a shunting device placed centrally in the brain, or, in some cases, by use of an endoscope going through the brain substance to its central part. The main problem in the industry is that conventional treatment systems (shunts) are based on a technology from 1950s and they are failing on average in 4-8 years, due to blockage or over-drainage. This results in 100 000 re-operations annually and brings a lot of complications (incl. increased infections) to the patient. Furthermore, this inefficiency represents an additional cost of €1.5B for the health care systems annually. To offer a solution to these problems, CSF-Dynamics is developing a new disruptive implantable medical device for treatment of hydrocephalus. The main innovation is draining the cerebrospinal fluid into sinus vein that is a natural resorption place of CSF, instead of conventional chest or abdomen. The hunt system uses novel stent technology as an outlet into the sinus vein, to avoid obstruction. SinuShunt competitive advantages are: 1) significantly increased life-time of the shunt, therefore reducing amount of re-operations; 2) Better quality of life for the patient due to the close to normal drainage of the brain-fluid, avoiding over-drainage and complications thereof. Hydrocephalus market is currently valued at €1.2B and is expected to reach a value of €1.6B by 2023. The market is steadily growing at CAGR of 4.4% during this time period. The market growth is propelled by growth in aging of population, increasing awareness of the condition and constantly improving diagnostic tools. Our end-users are hydrocephalus patients and users neurosurgeons. By 2026 we expect to sell our solution internationally, employ additional 112 people, and achieve a ROI of 40.6.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

SME-2 - SME instrument phase 2

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

CSF-DYNAMICS A/S
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 698 862,50
Address
GAMMEL LUNDTOFTEVEJ 1 D
2800 KGS. LYNGBY
Denmark

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 998 375,00
My booklet 0 0